| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Co-Diagnostics, Inc.$2.36
-0.08 (-3.28%)
B 76Pipeline Score MedTech · Commercial
Market Cap
18.26 M
EPS
-28.01
P/E Ratio
-
Value Trade
6.47 M
SEC Financials
Q1 2026Dilution Risk
Revenue
145.95 K
R&D Expenses
5.93 M
Operating CF
-7.85 M
Total Assets
21.50 M
Total Liabilities
5.46 M
Equity
16.04 M
D/E Ratio
12,345
249.66 %
Week
200 %
1 Month
107.79 %
3 Month
-49.55 %
6 Month
-98.13 %
5 Year
-97.18 %
All Time
Cash Data
Cash Position
8.23 M
Monthly Burn
2.62 M
Runway
0.9 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
173.88 K
52 Week Range
1.26 - 46.50
% held by Insiders
5.23 %
% held by Institutions
5.43 %
Enterprise Value
12.06 M
Total Shares
3.60 M
Short %
2.51 %
Float Shares
3.47 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Co-Diagnostics, Inc.
387Total events
12Upcoming
73Tier-1 (high impact)
2019 – 2026Coverage
Upcoming catalysts 2
TBD
T3Manufacturing Milestone
Subscribe to view catalyst details
TBD
T1NDA Submission
Subscribe to view catalyst details
Event history 2
TBD
▲Other Regulator MilestoneEx-US Regulatory
Subscribe to view catalyst details
TBD
▲Enrollment CompleteTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
B76
Pipeline Score $275M
Pipeline ValueValuation Signal
677
Drugs Scored15.0x
rNPV / MCap Top 97%
Micro Cap (rank 28 of 913)
Percentile RankCo-Diagnostics, Inc. holds a solid B-grade pipeline (76/100), with $95.9B risk-adjusted pipeline value, led by DWP16001 in T2DM (Type 2 Diabetes Mellitus) (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DWP16001 Small molecule | T2DM (Type 2 Diabetes Mellitus) | Phase 3 | NCT07619833 | 58% | $7.5B | NOT YET_RECRUITING | 510 | VERY_FAST | B (62) | Nov 1, 2027 | - | Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CODX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CODX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CODXCo-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer
Co-Diagnostics has appointed Wes Lindsey, PhD, MBA, as the new Chief Scientific Officer. Dr. Lindsey brings over 20 years of experience in molecular diagnostics, having led numerous FDA submissions. His expertise is expected to significantly contribute to the regulatory processes and expansion of the Co-Dx PCR platform, which is currently under review.
Read more →CODXCo-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand
Co-Diagnostics has been invited to participate in the UNOPS Global Implementation Workshop on Near Point of Care TB Diagnostics in Bangkok. This workshop aims to enhance the implementation of WHO-recommended TB diagnostics by bringing together various stakeholders from 21 countries. Co-Diagnostics will showcase its PCR platform to facilitate discussions on improving TB diagnostic practices.
Read more →CODXCo-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test
Co-Diagnostics has completed clinical and analytical studies for its PCR Flu A/B & RSV test, preparing for a 510(k) submission to the FDA targeted for Q3 2026. The studies involved over 1,400 patients and extensive analytical testing, indicating a strong foundation for the submission. CEO Dwight Egan emphasized the significance of these milestones in advancing their diagnostic capabilities.
Read more →CODX▼ -14.6%on this news
Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States
Co-Diagnostics has expanded its Vector Smart division to include mosquito abatement districts in 21 states, adding four new laboratory installations in June 2026. This growth coincides with a webinar aimed at prospective customers during National Mosquito Control Awareness Week. The company's technology supports in-house PCR testing, improving disease surveillance and operational decisions for public health agencies.
Read more →CODXCo-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing Line
Co-Diagnostics, Inc. hosted a delegation from CoMira Diagnostics in Utah to unveil a future automated manufacturing line. This event marks a significant step in their joint venture aimed at enhancing diagnostic capabilities in Saudi Arabia and surrounding regions. The partnership is expected to leverage advanced technology, including AI, to improve healthcare solutions. The visit included local dignitaries, emphasizing the collaboration's importance to both parties.
Read more →CODXCo-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement
Co-Diagnostics has entered an exclusive distribution agreement with a partner in Mexico to advance the commercialization of its Co-Dx PCR Pro platform. This agreement aims to expand the company's presence in Latin America and support the introduction of various molecular diagnostics products. The partnership has previously generated significant revenue and played a crucial role during the COVID-19 pandemic.
Read more →CODX▼ -19.9%on this news· ran to -33% by day 1
Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
Co-Diagnostics, in collaboration with CoSara Diagnostics, is advancing its Ebola PCR test development, focusing on a dual-assay strategy to enhance outbreak response capabilities. This includes a blood-based assay for the Co-Dx PCR platform, expanding its testing capabilities beyond swabs. The company aims to improve accessibility to molecular diagnostics for infectious diseases in various markets.
Read more →CODX▲ +79.7%on this news
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
Co-Diagnostics has advanced its PCR assay development strategy for the Bundibugyo virus in collaboration with CoSara Diagnostics. This initiative aims to meet international deployment needs amid the ongoing Ebola outbreak in the DRC and Uganda. The joint venture is expected to facilitate rapid diagnostics in response to emerging healthcare crises. The WHO has declared the outbreak a public health emergency, highlighting the urgency of the situation.
Read more →CODX▲ +21.3%on this news· ran to +362% by day 3shared move
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Co-Diagnostics, Inc. has announced a private placement to raise $3.0 million by selling 1,647,447 shares of common stock along with warrants. The offering is priced at $1.821 per share and is expected to close around May 21, 2026. Maxim Group LLC is the sole placement agent for this transaction, which is being conducted under Nasdaq rules.
Read more →CODX▼ -19.9%on this news· ran to +106% by day 3shared move
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
Co-Diagnostics has announced the completion of its assay development strategy for the Bundibugyo virus, linked to the recent Ebola outbreak in the DRC and Uganda. The company emphasizes the importance of rapid testing and decentralized diagnostics in managing public health emergencies. Enhanced traveler screening measures have been implemented by the CDC following the outbreak declaration by WHO.
Read more →CODXCo-Diagnostics Reports First Quarter 2026 Financial Results Advancing Global Commercialization Through CoSara Regulatory Progress and Regional Expansion Executing Clinical Strategy with Upper Respiratory Submission Prepa
Co-Diagnostics, Inc. has reported its financial results for the first quarter of 2026, highlighting regulatory and commercial advancements including a CDSCO license in India. The company achieved a revenue of $0.15 million, marking a year-over-year increase, while facing higher operating losses and decreased cash reserves. The firm plans to expand its presence in South Asia and aims for further clinical advancements with ongoing submissions and studies related to its diagnostic platform. Overall, the company's strategic initiatives aim at enhancing commercialization efforts amid ongoing financial challenges.
Read more →CODX▲ +31.1%on this news
Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City
Co-Diagnostics has announced the finalization of a lease for its manufacturing facility in Sudair Industrial City, Saudi Arabia, through its joint venture CoMira Diagnostics. This milestone is part of the company's strategy to enhance domestic manufacturing capabilities in alignment with Saudi Arabia's Vision 2030. The facility will focus on producing diagnostic instruments and is expected to streamline regulatory processes for market entry.
Read more →CODXCo-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast
Co-Diagnostics, Inc. has announced the date for its first quarter 2026 earnings release, which is scheduled for May 14, 2026, after market close. The company will also hold a conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial results. Key management will participate in the call.
Read more →CODXCo-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.
Co-Diagnostics has been invited to present its Co-Dx Mycobacterium tuberculosis test at the Stop TB Partnership Summit in Washington, D.C. on April 17, 2026. This event aims to connect U.S. private sector innovators with government agencies to enhance the fight against tuberculosis. The company's testing platform aligns with recent WHO guidelines, which may facilitate broader application in TB diagnostics. However, the technologies are still pending regulatory approval before being marketed.
Read more →CODXCo-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany
Co-Diagnostics, Inc. will participate in the ESCMID Global 2026 event in Munich, Germany, from April 17-21. This engagement aims to expand international relationships with customers and distributors while showcasing the company's CE-IVD testing solutions and the forthcoming Co-Dx PCR platform. The event highlights significant advancements in clinical microbiology and infectious diseases, attracting a global audience. Attendees will have the opportunity to visit the company's booth to learn more about its offerings.
Read more →CODXCo-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah
Co-Diagnostics, Inc. executives will join Utah Governor Cox on a trade mission to Switzerland and Germany from April 13-22, 2026. The mission aims to strengthen commercial and institutional ties with Europe’s leading diagnostics and technology sectors. During the trip, executives will visit key organizations, including Roche Diagnostics, to explore collaboration opportunities. This initiative aligns with the company's efforts to prepare for the FDA submission of its real-time PCR point-of-care diagnostic platform.
Read more →CODXCo-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City
Co-Diagnostics' joint venture, CoMira, has received approval for a manufacturing facility in Sudair Industrial City, Saudi Arabia. This facility aims to enhance local production of molecular diagnostic solutions, aligning with the Kingdom's Vision 2030 strategy. The project is expected to support CoMira's international expansion while addressing local healthcare needs. However, there are risks related to lease execution and regulatory approvals.
Read more →CODX▲ +9.4%on this newsshared move
Co-Diagnostics Reports Full Year 2025 Financial Results Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures Progressing Clinical Pipeline and Regulatory Pathways for PCR Platform Strength
Co-Diagnostics, Inc. released its financial results for 2025, highlighting a significant decline in revenue, primarily attributed to lower grant revenue. The company reported a net loss increase to $46.9 million, impacted by a major impairment charge. Despite financial challenges, Co-Diagnostics has made strides in advancing its global commercialization strategy, particularly through joint ventures in India and Saudi Arabia. The company is also progressing in clinical evaluations and integrating AI into its diagnostic platform, aiming for commercialization in 2026.
Read more →CODX▼ -13.2%on this news· ran to -25% by day 3
Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization
Co-Diagnostics has begun shipping diagnostic materials to India to initiate clinical studies for its tuberculosis test, aligning with new WHO recommendations for near-point-of-care testing. The company's proprietary PCR platform is designed for easy sample collection, including tongue swabs. Encouraging preclinical results have been reported, and the company is preparing for regulatory submissions in India.
Read more →CODXCo-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia
Co-Diagnostics has signed an agreement to expand its commercial and distribution territory across South Asia, including Bangladesh, Pakistan, Nepal, and Sri Lanka. This expansion increases the addressable market to an estimated $13 billion and supports the commercialization of its PCR Pro and SARAGENE product lines. The company is focused on establishing distribution channels and partnerships in these new markets, with plans for future distributor engagement activities.
Read more →CODXCo-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast
Co-Diagnostics, Inc. announced the release date for its fourth quarter and full year 2025 earnings, scheduled for March 31, 2026. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results with analysts. Key management will participate in the call, emphasizing the company's commitment to transparency and stakeholder engagement.
Read more →CODX▼ -10.7%on this newsshared move
Co-Diagnostics to Present at Medical Korea 2026
Co-Diagnostics, Inc. will be attending Medical Korea 2026 in Seoul, South Korea, from March 19-22. The company will join Utah’s World Trade Center delegation, participating in a healthcare business roundtable and presenting its upcoming Co-Dx PCR point-of-care platform. This annual event aims to foster healthcare collaborations, drawing participants from over 50 nations. Attendees will have the opportunity to learn more about Co-Dx’s innovative diagnostic solutions, which align with the conference's theme of AI-powered global healthcare.
Read more →CODX▲ +6.5%on this newsshared move
Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies
Co-Diagnostics, Inc. has been granted a Japanese patent for its Co-Dx PCR platform technologies, enhancing its intellectual property portfolio. The patent, which includes 34 claims, supports the company's strategy to provide affordable point-of-care PCR testing solutions. This development follows a similar patent granted in Australia, reinforcing Co-Diagnostics' competitive position in the market.
Read more →CODX▲ +101.8%on this newsshared move
Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements
Co-Diagnostics, Inc. announced on March 10, 2026, that it has regained compliance with the Nasdaq listing requirements, specifically the $1.00 bid price rule. This compliance allows the company to resume trading on Nasdaq starting March 11, 2026. The company aims to enhance its capital markets flexibility, which is expected to boost shareholder confidence while continuing efforts to finalize clinical studies and secure regulatory approvals for its Co-Dx PCR platform. However, the platform is currently not available for sale as it awaits FDA review.
Read more →CODXCo-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai
Co-Diagnostics, Inc. is set to participate in the World Health Expo Labs Dubai from February 10 to 13, 2026. This event will bring together professionals in laboratory science and diagnostics to discuss advancements in the field. Co-Diagnostics aims to expand access to high-quality molecular diagnostics in the Middle East and North Africa, further supported by its new joint venture, CoMira Diagnostics, with Arabian Eagle Manufacturing. The company will showcase its Co-Dx PCR platform, which is currently under clinical studies in the U.S.
Read more →CODXCo-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument
Co-Diagnostics, Inc. announced that its joint venture, CoSara Diagnostics, has received a CDSCO license to manufacture the CoSara PCR Pro instrument in India. This license represents the final regulatory requirement for commercialization and is expected to facilitate the regulatory process for associated PCR test kits in the future. Company executives expressed optimism that this achievement will enhance the availability of high-quality PCR diagnostics in regions where such tools are critically needed.
Read more →CODXCo-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform
Co-Diagnostics, Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd., has achieved ISO 13485:2016 certification for its manufacturing facility in India. This certification is seen as a critical step for the regulatory clearance of their upcoming PCR platform and other medical devices. The ISO designation affirms compliance with international quality management standards and should facilitate access to markets and enhance trust among stakeholders. The achievement coincided with visits from Co-Dx staff to finalize software and support upcoming clinical performance studies.
Read more →CODX▼ -60.5%on this news
Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships
Co-Diagnostics, through its joint venture CoSara, is actively participating in regional conferences in India to strengthen its distributor relationships. The company is introducing its SARAGENE® diagnostic products and preparing for clinical studies related to the Co-Dx PCR Mycobacterium Tuberculosis Test. CoSara's involvement aligns with India's manufacturing initiative, showcasing its commitment to local production.
Read more →CODX▼ -21.2%on this news
Co-Diagnostics Announces Reverse Stock Split
Co-Diagnostics, Inc. announced a 1-for-30 reverse stock split effective January 2, 2026, to comply with Nasdaq's minimum bid price requirement. This decision follows stockholder approval at a special meeting held on December 5, 2025. The split will affect all outstanding shares and stock options, with no fractional shares issued.
Read more →CODXCo-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
Co-Diagnostics has received an Australian patent for its Co-Dx PCR platform, marking a significant milestone in its intellectual property strategy. This patent, the first for the new point-of-care testing system, protects the design and operation of the Co-Dx PCR Pro instrument and its test cups. The company aims to enhance PCR testing accessibility, especially in decentralized environments.
Read more →CODX▲ +5.3%on this news
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
Co-Diagnostics has conducted an in silico analysis confirming that its Logix Smart ABC test remains effective against the influenza A H3N2 subclade K. This analysis showed high homology with 3,900 influenza sequences, indicating the test's sensitivity is stable. The company is also preparing for clinical performance testing of a new multiplex test aimed at FDA clearance.
Read more →CODX▲ +5.3%on this newsshared move
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Co-Diagnostics, Inc. announced that its joint venture, CoSara Diagnostics, has been invited to participate in the 2nd Advanced TB Diagnostics Course in Chennai, India. This event, organized by ICMR-NIRT and other global health organizations, aims to enhance tuberculosis detection and implementation strategies. The workshop will feature sessions and discussions led by leading experts and industry innovators, focusing on available technologies and strategies to improve case-finding in South-East Asia. CoSara's involvement highlights the company's commitment to addressing the challenges in TB diagnostics.
Read more →CODXCo-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025
Co-Diagnostics, Inc. announced its presentation at the Point-of-Care Testing 2025 Conference in Boston. The presentation will focus on the Co-Dx PCR platform and its integration with AI to enhance real-time diagnostics. The event aims to highlight advancements in patient-centered care and mobile testing technologies. The Co-Dx PCR platform is currently under regulatory review.
Read more →CODXCo-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
Co-Diagnostics announced that its joint venture, CoSara, will participate in VIROCON 2025 in Pune, India. The event will showcase CoSara's advancements in preclinical studies for tuberculosis and HPV tests. These studies are crucial for regulatory submissions and highlight the company's innovative approach in molecular diagnostics. Attendees can learn more about CoSara's products at their booth.
Read more →CODX▼ -5.8%on this news
Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
Co-Diagnostics, Inc. presented at the 2025 World Conference on Lung Health, discussing the adoption of its tuberculosis molecular diagnostic test. The company plans to begin clinical performance testing of its new PCR test kit, targeting markets in India and South Africa. Additionally, Co-Diagnostics is considering a strategic transaction with its Indian joint venture, CoSara Diagnostics.
Read more →CODX▲ +13.4%on this newsshared move
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA
Co-Diagnostics has commenced clinical evaluations for its Co-Dx PCR Flu A/B, COVID-19, RSV Test Kit, aiming for FDA 510(k) clearance. The test is designed for simultaneous detection of multiple respiratory infections. The company anticipates significant market opportunities, particularly in North America and the Middle East, as it prepares for regulatory submissions.
Read more →CODX▼ -10.9%on this newsshared move
Co-Diagnostics Reports Third Quarter 2025 Financial Results
Co-Diagnostics reported its third quarter 2025 financial results, highlighting significant strategic initiatives including a joint venture in Saudi Arabia and the launch of an AI business unit. The company aims to enhance its market presence and unlock value through potential strategic transactions. However, the regulatory review of its diagnostic platform remains a key consideration.
Read more →CODXUtah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia
Co-Diagnostics, Inc. has announced a joint venture named CoMira Diagnostics in Saudi Arabia, recognized by Utah Governor Spencer Cox and BioUtah's Kelvyn Cullimore. This partnership signifies the company's ongoing expansion in the Middle East and North Africa, reflecting the strength of Utah's life sciences sector. The recognition emphasizes Co-Diagnostics' role in advancing global healthcare.
Read more →CODXCo-Dx Fireside Chat with KCSA
Co-Diagnostics, Inc. provided a brief overview of their company and contact information. The article includes details about their trademarks and services. However, it lacks specific news or updates regarding their operations or products.
Read more →CODXCo-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd
Co-Diagnostics has engaged Maxim Group as its exclusive financial advisor to explore strategic alternatives for its Indian joint venture, CoSara Diagnostics Pvt. Ltd. This includes the possibility of merging with a Special Purpose Acquisition Company (SPAC). The goal is to unlock value for CoSara and its shareholders while focusing on manufacturing molecular diagnostics products for international markets, particularly India.
Read more →CODX▼ -12.2%on this newsshared move
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
Co-Diagnostics has established a new artificial intelligence business unit led by Christopher Thurston. This initiative aims to integrate existing and future AI applications into the Co-Dx Primer Ai platform, enhancing the efficiency of AI-powered diagnostics. The company expects this move to improve situational awareness during health crises and potentially predict outbreaks.
Read more →CODX▼ -6%on this news· ran to -20% by day 3shared move
Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast
Co-Diagnostics, Inc. has announced the release date for its third quarter 2025 earnings, scheduled for November 13, 2025, after market close. The company will also host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial results. Key management will participate in the call, enhancing communication with investors.
Read more →CODXCo-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia
Co-Diagnostics, Inc. will host a virtual fireside chat on November 5, 2025, featuring CEO Dwight Egan. The discussion will focus on the company's growth initiatives, particularly a definitive agreement with Arabian Eagle to form CoMira Diagnostics in Saudi Arabia. This partnership aims to enhance the deployment of Co-Dx's PCR platform across the Middle East.
Read more →CODX▼ -13.4%on this news· ran to -29% by day 3shared move
Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Co-Diagnostics, Inc. has successfully closed a registered direct offering of 12,727,272 shares of common stock at a price of $0.55 per share, generating gross proceeds of approximately $7.0 million. The proceeds will be utilized for the company’s working capital and general corporate purposes. The offering was conducted under a shelf registration statement deemed effective by the SEC earlier this year, with Maxim Group LLC serving as the placement agent. No offer to sell or solicitations are being made in jurisdictions where these actions would be considered unlawful.
Read more →CODX▼ -54.8%on this newsshared move
Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Co-Diagnostics, Inc. has announced a direct offering of common stock priced at $0.55 per share, aiming to raise approximately $7.0 million. The funds from this offering are expected to be allocated for working capital and general corporate purposes. The offering is set to close on or about October 29, 2025, pending the satisfaction of customary closing conditions. The securities are being offered under a shelf registration statement declared effective by the SEC in April 2023.
Read more →CODX▲ +259.3%on this newsshared move
Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle East
Co-Diagnostics has established a joint venture with Arabian Eagle Manufacturing to create CoMira Diagnostics in Saudi Arabia. This collaboration aims to localize the Co-Dx PCR platform across the Kingdom and 18 other countries within the MENA region. The partnership is geared towards supporting Saudi Vision 2030 by enhancing healthcare innovation and industrial growth. Both companies expect that regulatory clearance will improve market access within the territory. The initiative highlights the importance of advancing diagnostic technologies to better serve regional healthcare needs.
Read more →CODX▼ -6%on this news· ran to +272% by day 3shared move
Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia
Co-Diagnostics, Inc. announced that its executive leadership will attend the Global Health Exhibition 2025 in Riyadh, Saudi Arabia, where they will host a booth to showcase their innovative diagnostic technologies. This participation follows a recent MOU for a joint venture with a regional company in Saudi Arabia to develop and distribute their products throughout the Middle East and North Africa. The exhibition expects over 160,000 healthcare professionals, providing a significant platform for Co-Diagnostics to highlight their upcoming Co-Dx PCR point-of-care platform.
Read more →CODX▼ -8.7%on this news
Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing
Co-Diagnostics, Inc. announced the development of a proprietary sample preparation instrument aimed at improving point-of-care PCR testing for tuberculosis (TB) in India. This device is designed to streamline sample processing and make TB diagnostics more accessible in nearly 30,000 primary health centers. With features ensuring user-friendliness and safety, the instrument represents a significant step towards decentralizing TB testing in resource-limited environments. Additionally, it may serve as a foundation for testing other pathogens, furthering Co-Diagnostics' mission of enhancing global healthcare accessibility.
Read more →CODXCo-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit
Co-Diagnostics, Inc. is scheduled to participate in the 2025 Maxim Growth Summit taking place on October 22-23 at The Hard Rock Hotel NYC. This event will host industry leaders and provide a platform for discussions across various sectors, including biotechnology and artificial intelligence. Co-Diagnostics plans to conduct one-on-one meetings with institutional investors, enhancing its networking and investment opportunities. Keynote speakers will include notable figures such as Larry Kudlow and Christopher Ruddy.
Read more →CODX▼ -7.1%on this news
Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30 Salt Lake City, Utah
Co-Diagnostics, Inc. will participate in the Lytham Partners Fall 2025 Investor Conference scheduled for September 30, 2025. The company will present a webcast and engage in one-on-one meetings with institutional investors. This event underscores Co-Diagnostics' commitment to showcasing its innovations in molecular diagnostics and may enhance its investor relations efforts.
Read more →CODXCo-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Co-Diagnostics, Inc. has successfully closed a registered direct offering, raising approximately $3.8 million by selling 9,619,000 shares of common stock at $0.40 each. The offering was made under the Nasdaq rules and is aimed at providing the company with working capital and supporting general corporate initiatives. The transaction was structured under an effective shelf registration statement with the SEC, facilitated by Maxim Group LLC as the placement agent.
Read more →CODX▼ -34.7%on this newsshared move
Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Co-Diagnostics, Inc. announced a successful registered direct offering of common stock, raising approximately $3.8 million. The company will offer 9,619,000 shares at an offering price of $0.40 per share. The proceeds are intended for working capital and other corporate needs. The offering is expected to close on September 18, 2025, subject to customary conditions. This move comes as the company aims to strengthen its financial position and support its diagnostic technology development.
Read more →CODX▲ +80.8%on this newsshared move
Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East
Co-Diagnostics, Inc. has signed a Memorandum of Understanding (MOU) with a manufacturing and distribution company in Saudi Arabia to form a joint venture focused on the development, manufacturing, and commercialization of its Co-Dx PCR platform across the Middle East and North Africa. The partnership will leverage local resources and expertise, aligning with the Saudi government's Vision 2030 initiatives, which may provide additional incentives for the venture. The CEO emphasized the company’s commitment to enhancing global access to PCR diagnostics through this strategic collaboration.
Read more →CODX▲ +12.2%on this news· ran to +108% by day 3shared move
Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains
Co-Diagnostics, Inc. has conducted an in silico analysis confirming the effectiveness of its Co-Primers-based PCR tests against chikungunya virus (CHIKV) strains. With nearly 250,000 CHIKV cases reported globally, the company's advancements in molecular diagnostics provide essential tools for accurate virus detection. Their Logix Smart ZDC Test allows for differentiation between CHIKV and similar viruses, which is crucial for appropriate patient management. The company's technology may significantly impact public health, especially in areas at risk for outbreaks.
Read more →CODXCo-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit
Co-Diagnostics, Inc. was honored at the Utah Business 2025 Innovation Awards Summit for its Co-Dx PCR platform in the Healthcare and Life Sciences category. CEO Dwight Egan accepted the award, emphasizing the significance of the recognition and the company's upcoming commercialization efforts. The Co-Dx PCR platform, which includes various components like the Co-Dx PCR Home and mobile app, is currently under review by regulatory bodies.
Read more →CODX▲ +8.8%on this news
Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.
Co-Diagnostics, Inc. is set to host a booth at the 17th Annual Next Generation Dx Summit in Washington, D.C. from August 18-20, 2025. This event serves as a key platform for industry leaders to engage in discussions on diagnostic advancements and technology innovations. At their booth, Co-Diagnostics will feature its Co-Dx Logix Smart® clinical solutions and preview their upcoming PCR diagnostics platform and tests targeting upper respiratory diseases, tuberculosis, and HPV, with clinical evaluations planned for 2025. Their participation is supported by a grant from World Trade Center Utah, reflecting institutional support for the company's initiatives.
Read more →CODXCo-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results Salt Lake City, Utah
Co-Diagnostics, Inc. reported financial results for the second quarter of 2025, revealing a significant decline in revenue to $0.2 million from $2.7 million in the same quarter last year. Operating expenses decreased by 19.1% to approximately $8.2 million, but the company still posted an operating loss of $8.1 million. Despite these challenges, Co-Diagnostics remains focused on its development goals for the Co-Dx PCR platform, which they believe will strengthen their regulatory submissions and commercialization efforts. The company did not recognize any grant revenue during this quarter, contributing to a net loss of $7.7 million.
Read more →CODXCo-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast
Co-Diagnostics, Inc. announced it will release its second quarter 2025 financial results on August 14, 2025, after market close. The company will hold a conference call and webcast at 4:30 p.m. ET on the same day to discuss these results with analysts. Key management, including the CEO, CFO, and Head of Investor Relations, will participate in the call. This event demonstrates the company's commitment to transparency and stakeholder engagement.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025
Co-Diagnostics, Inc. will host a booth at the World Health Expo Kuala Lumpur from July 16-18, 2025. This leading healthcare exhibition is expected to attract over 10,000 attendees from around the globe. The company plans to showcase its innovative PCR in vitro diagnostic technologies and highlight its new product developments. Additionally, company attendance is supported by a grant from World Trade Center Utah to foster international engagement and partnerships.
Read more →CODXCo-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference
Co-Diagnostics, Inc. announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. The conference aims to connect emerging growth companies with institutional investors. Company representatives will showcase the Co-Dx PCR testing platform, which is currently under FDA review and not available for sale yet.
Read more →CODXCo-Diagnostics, Inc. Reports First Quarter 2025 Financial Results
Co-Diagnostics, Inc. reported its financial results for Q1 2025, highlighting substantial advancements in its test pipeline, including plans for clinical evaluations and regulatory submissions for four key tests. CEO Dwight Egan emphasized the importance of the Co-Dx PCR platform in enhancing global diagnostic accessibility. The company aims to maintain operational efficiency as it progresses towards development milestones.
Read more →CODXCo-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast
Co-Diagnostics, Inc. has announced the release date for its first quarter 2025 financial results, set for May 8, 2025, after market close. The company will also host a conference call and webcast at 4:30 p.m. ET on the same day to discuss these results with analysts. Key management will participate in the call, ensuring direct communication with stakeholders.
Read more →CODXPLAN OF DISTRIBUTION We have entered into the Amended and Restated Equity Distribution Agreement dated
CODX has entered into an amended Equity Distribution Agreement allowing it to sell shares of common stock up to an aggregate of $17,111,650 through designated sales agents, Piper Sandler and Clear Street LLC. The sales agents are obligated to sell the shares using commercially reasonable efforts. Compensation terms have been set, including a 3.0% commission on gross sales and up to $250,000 in estimated offering expenses. The agreement is governed by regulatory standards and may be terminated with notice by either party.
Read more →CODX▼ -6%on this news· ran to -23% by day 1
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results
Co-Diagnostics, Inc. has reported financial results for 2024, revealing a revenue decrease to $3.9 million, down from $6.8 million in 2023, attributed largely to a drop in product sales. Although operating expenses fell by 5.2%, the company experienced a net loss of $37.6 million for the year. Significant business developments include the inauguration of new manufacturing facilities and advancements in regulatory strategy, particularly concerning the withdrawal of a 510(k) application for the Co-Dx PCR platform. The company remains optimistic about its diagnostic pipeline, which includes tests for tuberculosis and HPV multiplexing, and plans to achieve operational efficiencies moving forward.
Read more →CODXCo-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast
Co-Diagnostics, Inc. has announced that it will release its fourth quarter and full year 2024 earnings results on March 27, 2025, following the market close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss these financial results with analysts. Among the participants will be the CEO, CFO, and Head of Investor Relations. This release and the subsequent discussions highlight the company's ongoing commitment to transparency and investor communication.
Read more →CODXCo-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit
Co-Diagnostics, Inc. announced the dismissal of a securities class action lawsuit on March 4, 2025. The case, filed by Gelt Trading, alleged violations concerning the accuracy of the Company's COVID-19 test claims. The court ruled that the plaintiff failed to demonstrate loss causation and excluded expert testimony supporting their claims. The Company considers this dismissal a significant win and is eager to move forward.
Read more →CODXNasdaq Live from MarketSite Interview with Dwight Egan
The article provides basic information about Co-Diagnostics, Inc. and its trademarks. It includes contact details and legal disclaimers regarding the use of the company's trademarks. There is no specific news or event discussed in the content.
Read more →CODXCo-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025
Co-Diagnostics, Inc. (CODX) will co-host a symposium titled "HPV and Cancer: Exploring Advances in Prevention and Care" on March 4, 2025, in Baroda, India, coinciding with International HPV Awareness Day. The event, in partnership with CoSara Diagnostics, seeks to highlight advancements in cancer prevention and care with contributions from various experts in the field. Co-Diagnostics is also progressing on its HPV multiplex test using its Co-Dx PCR platform, aimed at enhancing screening accessibility in low- and middle-income countries. The symposium aligns with efforts to educate the public on HPV and reduce its associated health risks.
Read more →CODX▼ -13.4%on this news· ran to -28% by day 3
CoSara Diagnostics Observes World Cancer Day with Cancer Awareness Event
CoSara Diagnostics celebrated World Cancer Day 2025 by hosting a lecture series focused on cancer awareness in Vadodara, Gujarat. The event featured discussions on cancer prevention, diagnosis, and nutrition, with expert speakers sharing insights. CoSara emphasized its commitment to improving cancer diagnostics and access to care, particularly regarding HPV-related cancers.
Read more →CODXCo-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a te
Co-Diagnostics, Inc. has announced its decision to withdraw the current 510(k) submission for its COVID-19 test based on FDA feedback regarding shelf-life stability. The company intends to submit an enhanced version of the test that addresses these concerns and incorporates recent technological developments to improve operational efficiencies. The new submission is expected to be supported by additional clinical evaluation data. Co-Dx remains focused on executing its development and commercialization plans for its PCR platform.
Read more →CODXCo-Diagnostics, Inc. to Exhibit at BioUtah
Co-Diagnostics, Inc. will exhibit at BioUtah's Life Sciences Day at the Utah State Capitol Rotunda, showcasing its cutting-edge Co-Dx PCR testing platform. This platform is designed for detecting various infectious diseases including COVID-19, and incorporates cloud-based analysis for tracking outbreaks. The event reflects the company’s ongoing efforts to strengthen relationships within the life sciences community, following their recent participation in an Asia trade mission. Over 25 companies will participate in this event, enhancing collaboration among industry peers.
Read more →CODX▼ -13.6%on this news· ran to -24% by day 3
Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025
Co-Diagnostics, Inc. announced its participation in Nasdaq's Live from MarketSite broadcast at the Silicon Slopes Summit 2025, scheduled for January 14, 2025. The discussion will revolve around its upcoming Co-Dx PCR platform and various diagnostic tests for diseases such as COVID-19 and mpox. The company also emphasizes its preparedness for potential health crises related to infectious diseases. Current products are under FDA review, while a post-holiday surge of COVID-19 highlights the ongoing challenges in public health.
Read more →CODX▼ -5%on this news
Co-Dx and CoSara inaugurate oligo synthesis facility in Ranoli, India
Co-Dx and CoSara Diagnostics inaugurated an oligonucleotide synthesis facility in Ranoli, India, aimed at manufacturing Co-Primers in-house. This facility is the first in Gujarat and aligns with the 'Make in India' initiative, facilitating access to the healthcare market. The companies plan to launch tests for TB and HPV, addressing significant health challenges in the region.
Read more →CODXCo-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility
Co-Diagnostics, Inc. has announced the inauguration of CoSara Diagnostics' new oligonucleotide synthesis facility in Ranoli, India, set for December 11, 2024. This facility aims to support the 'Make in India' initiative by producing Co-Primers in-house, which are essential for PCR diagnostic tests. The creation of this facility is seen as a significant step towards enhancing manufacturing efficiency and expanding Co-Dx's presence in the Indian healthcare marketplace. However, the Co-Dx PCR platform is still under regulatory review and not yet available for sale, adding an element of uncertainty to the company's future operations in the region.
Read more →CODXThe History of Tuberculosis Diagnostics
The article traces the history of tuberculosis (TB) diagnostics from ancient times to the present. It highlights significant milestones, including Dr. Robert Koch's discovery of M. tuberculosis in 1882 and the evolution of diagnostic methods. Despite advancements, challenges remain, particularly in accessibility and detection rates, with a focus on the potential of new technologies like Co-Dx™ PCR to improve TB diagnostics.
Read more →CODXCo-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results
Co-Diagnostics, Inc. reported its financial results for the third quarter of 2024, showing a significant decline in revenue from $2.5 million to $0.6 million due to timing of grant revenue recognition. The company's operating loss increased to $10.2 million and net loss rose to $9.7 million, with adjusted EBITDA loss at $8.8 million. Despite these setbacks, Co-Diagnostics announced progress in its diagnostic test development and an expansion of its business line, maintaining a dialogue with the FDA regarding regulatory submissions.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024
Co-Diagnostics, Inc. announced its participation at the MEDICA 2024 trade fair in Düsseldorf, Germany, which will take place from November 11-14. The company will host a booth and deliver a presentation on its upcoming Co-Dx PCR platform, showcasing its advancements in point-of-care and over-the-counter diagnostics. MEDICA is recognized as the largest medical B2B trade fair globally, expected to attract significant attention from a diverse international audience. Co-Diagnostics aims to leverage this platform to promote its diagnostic technologies, although some products remain under FDA review and are not yet available for sale.
Read more →CODXBenefits of PCR Testing
PCR technology, celebrating over 40 years, remains the gold standard for infectious disease diagnostics due to its sensitivity and specificity. Recent advancements aim to make PCR testing more accessible outside traditional lab settings, including at-home testing options. Innovations like the Co-Dx PCR Pro are set to enhance immediate diagnostic capabilities for various pathogens.
Read more →CODXCo-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast
Co-Diagnostics, Inc. has announced it will release its third quarter 2024 earnings results on November 7, 2024, after market close. The company will also conduct a conference call and webcast at 4:30 p.m. ET on the same day, aimed at discussing the financial results with analysts and investors. This event will feature key management personnel including the CEO and CFO, emphasizing the company's commitment to communication with stakeholders.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at Medlab Africa in Cape Town on Oct 22-24, 2024
Co-Diagnostics, Inc. announced that it will host a booth at the Africa Health/Medlab Africa conference in Cape Town from October 22-24, 2024. This event is expected to provide valuable insights into markets that are crucial for the company’s future growth. Co-Diagnostics is working on various tests for infectious diseases, including tuberculosis. The company reported favorable results for its Logix Smart mpox test, which currently shows full reactivity against known strains. However, the association of their products with regulatory reviews presents potential challenges.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3
Co-Diagnostics, Inc. will host a booth at the UHCA/UCAL Fall Convention & Expo on October 2-3, 2024, in Sandy, Utah. The event will feature their upcoming Co-Dx PCR platform, highlighting at-home and point-of-care tests in development. This convention aims to engage leaders in the skilled nursing and assisted living sectors, providing Co-Diagnostics a platform for visibility. However, the products showcased are currently under FDA review and not available for commercial sale.
Read more →CODXCo-Diagnostics, Inc. to Accompany Utah Governor and WTC Utah on Trade Mission to South Korea and Japan
Co-Diagnostics, Inc. announced participation in a trade mission to South Korea and Japan, led by Utah Governor Spencer Cox. The mission aims to boost international relationships and access to high-quality PCR diagnostics. Co-Dx has previously established a joint venture in India and has distributed millions of COVID-19 tests globally. This initiative aligns with the company’s goals of improving patient care access and preparing for the launch of new diagnostic technologies.
Read more →CODXWest Nile, dengue and other arbovirus patterns are changing with the climate
Experts warn that climate change is altering mosquito activity patterns, leading to heightened public health risks from arboviruses. Warmer temperatures and changing rainfall are expanding mosquito populations into new areas, increasing the likelihood of outbreaks. The rise in diseases such as dengue and West Nile emphasizes the need for advanced mosquito abatement technologies, including real-time PCR solutions. Without immediate action, the health impacts could worsen significantly.
Read more →CODX▲ +6.8%on this news
Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test
Co-Diagnostics, Inc. announced favorable results from a recent in silico analysis of its Co-Dx Logix Smart Mpox 2-Gene RUO test, indicating it retains full reactivity against current mpox strains, including clade Ib. This follows a public health emergency declaration regarding mpox by health authorities in Africa and the WHO. The company has received high demand for its test kits globally, emphasizing its commitment to accessible diagnostics. However, clade Ib's higher severity and the status of regulatory reviews for their PCR platform pose ongoing challenges.
Read more →CODXADLM 2024
Co-Dx participated in the ADLM 2024 annual meeting, showcasing their advancements in PCR diagnostics. The event featured a booth, a scientific poster on COVID-19 testing, and a presentation on the role of their PCR platform in improving global diagnostics. The company aims to enhance accessibility to high-quality diagnostics, particularly for tuberculosis. Their poster was one of four selected for an in-depth presentation, highlighting the platform's potential.
Read more →CODXCo-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.
Co-Diagnostics, Inc. announced its sponsorship and presentation at the 16th Annual Next Generation Dx Summit in Washington, D.C. from August 19-21, 2024. CEO Dwight Egan will present on the Company's forthcoming PCR platform, which is currently under FDA review. The summit will focus on advancements in diagnostics, including the Co-Dx Smart suite of clinical laboratory solutions and Research Use Only tests for mpox. The participation highlights Co-Diagnostics' role in the evolving diagnostics landscape.
Read more →CODXCo-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results
Co-Diagnostics, Inc. reported its financial results for the second quarter of 2024, showcasing a substantial increase in revenue to $2.7 million, largely attributed to milestones achieved through grant agreements. Operating losses decreased to $7.7 million, reflecting cost control efforts, while net losses also saw a reduction. The company has made significant progress by submitting its first 510(k) application to the FDA for the Co-Dx PCR Pro Platform and inaugurated a new manufacturing facility. Despite the positive trends, the company continues to face challenges with substantial net losses and ongoing FDA reviews for its products.
Read more →CODXCo-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago
Co-Diagnostics, Inc. is participating in the ADLM 2024 annual meeting in Chicago, showcasing its innovative at-home and point-of-care Co-Dx PCR platform. The company will present its technological advancements that aim to address various global diagnostics gaps, including tuberculosis, during a scheduled presentation featuring CEO Dwight Egan. Additionally, the company will be highlighting its existing and upcoming testing products. Important to note, the Co-Dx PCR platform is still subject to FDA review and is not yet available for commercial sale.
Read more →CODX▼ -9.1%on this newsshared move
Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast
Co-Diagnostics, Inc. has announced that it will release its second quarter 2024 earnings on August 8, 2024, after market close. The company will also host a conference call and webcast to discuss these financial results with analysts and institutional investors. The call will feature key management members, including the CEO and CFO. This transparent approach demonstrates the company's commitment to keeping stakeholders informed about its performance.
Read more →CODXCo-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States
Co-Diagnostics, Inc. announced the expansion of its vector control technology to its 15th U.S. state, Nevada. The company's Vector Smart PCR tests are used in environmental surveillance to detect mosquito-borne pathogens such as West Nile virus and Zika. The technology allows mosquito abatement districts to obtain rapid testing results, improving prevention measures against disease transmission. The CEO emphasized the growing need for effective surveillance as climate change increases mosquito populations capable of spreading harmful illnesses.
Read more →CODX▲ +5.5%on this news
Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21
Co-Diagnostics, Inc. announced its participation at the FIME 2024 medical trade show, scheduled for June 19-21 in Miami Beach. The company will be presenting its Co-Dx PCR platform at the Utah booth, which aims to forge new supplier relationships with attendees from around the globe. Although the platform has undergone a recent application for FDA clearance, it is not currently available for sale. The event will feature participants from over 116 countries, providing Co-Diagnostics a platform to enhance its market presence.
Read more →CODX▼ -6.5%on this newsshared move
Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in th
Co-Diagnostics, Inc. has announced the submission of its first FDA 510(k) application for the Co-Dx PCR Pro platform and COVID-19 test for OTC use. The application aims to facilitate decentralized PCR diagnostics, thereby enhancing accessibility for infectious diseases. The company plans to pursue further clearances for additional tests in its pipeline, including those for tuberculosis and respiratory viruses. However, the platform is still under FDA review, delaying commercial availability.
Read more →CODXCo-Diagnostics, Inc. Reports First Quarter 2024 Financial Results
Co-Diagnostics, Inc. announced its financial results for Q1 2024, reporting a decline in revenue to $0.5 million and an increased net loss of $9.3 million. Operating expenses rose due to heightened R&D costs, contributing to an operating loss of $10.3 million. Despite these financial setbacks, the company highlighted significant operational developments, including the opening of a new manufacturing facility in South Salt Lake and the appointment of new executive leadership. Future plans include submitting a 510(k) application to the FDA for a new instrument and COVID-19 test kit.
Read more →CODXCo-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast
Co-Diagnostics, Inc. has announced that it will release its financial results for the first quarter of 2024 on May 9, 2024. Following the release, the company will host a conference call and webcast to discuss these results with analysts and institutional investors. The call will feature executives including the CEO and CFO, and will be accessible both live and recorded for future viewing. This move highlights Co-Diagnostics' commitment to transparency and stakeholder engagement.
Read more →CODXCo-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan
Co-Diagnostics, Inc. announced its participation in the 9th Asia Pacific Region Conference (APRC) in Taipei, Taiwan, from April 26-29, 2024, where the theme is improving holistic healthcare. The company's Executive VP, Joseph Featherstone, will present on accessible TB diagnostics using the Co-Dx PCR Pro on April 27. The conference aims to bring together leaders in tuberculosis and respiratory infectious diseases to share advancements and innovations. Co-Dx invites attendees to visit Booth B20 for insights into its diagnostic technologies, including the upcoming Co-Dx PCR Pro instrument.
Read more →CODXCo-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event
Co-Diagnostics, Inc. has inaugurated a new manufacturing facility in South Salt Lake, Utah, showcasing its commitment to enhancing local and international diagnostics capabilities. The event was attended by local dignitaries, who praised the company's efforts to create jobs and drive economic growth in the region. While the company aims to close the gap in access to high-quality diagnostics, its Co-Dx PCR platform and related products remain under FDA review and are not currently available for purchase.
Read more →CODXCo-Diagnostics, Inc. Appoints New President and Other C-Level Positions
Co-Diagnostics, Inc. has appointed Richard Abbott as President, along with David Nielsen as COO, Christopher Thurston as CTO, and Seth Egan as CCO. These appointments come as the company aims to advance its Co-Dx PCR platform for molecular diagnostics. The experience of the new leaders is expected to bolster the development and commercialization of the platform and its associated tests. The company highlights its mission to ensure equitable access to diagnostics as a key focus moving forward.
Read more →CODX▲ +6.4%on this news
Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address
Co-Diagnostics, Inc. CEO Dwight Egan announced the opening of a new manufacturing facility in Salt Lake City, UT, during the 5th Annual MarketsandMarkets conference in London. The company is expanding its manufacturing capabilities in both Utah and India to support its new PCR platform and related products, including tests for tuberculosis. The Co-Dx PCR platform and associated tests await FDA review, impacting their market availability. Egan emphasized the company's commitment to equitable diagnostics, particularly against diseases like TB, which remains a significant health challenge in India.
Read more →CODXCo-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England
Co-Diagnostics, Inc. has announced that CEO Dwight Egan will deliver a keynote address at the MarketsandMarkets 2024 conference in London, focusing on the potential impacts of their Co-Dx PCR platform. The conference, occurring on March 21-22, 2024, aims to gather healthcare leaders to discuss advancements in diagnostics. Additionally, the company's Executive VP will present on accessible TB diagnostics in low- and middle-income countries. The Co-Dx PCR platform is currently under review for regulatory approval.
Read more →CODXCo-Diagnostics, Inc. Reports Full Year 2023 Financial Results
Co-Diagnostics, Inc. announced its financial results for the full year 2023, revealing a substantial decline in revenue to $6.8 million from $34.2 million in 2022. The company reported an increase in operating loss to $42.7 million, alongside a net loss of $35.3 million for the year. Despite financial challenges, Co-Diagnostics progressed in clinical evaluations and received significant grant funding for developing new diagnostic tests. The company also initiated construction of a new manufacturing facility.
Read more →CODXCo-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test
Co-Diagnostics, Inc. has announced that its joint venture, CoSara Diagnostics Pvt Ltd, received clearance from India's Central Drugs Standard Control Organization (CDSCO) to manufacture and sell the SARAPLEX Influenza Multiplex Test Kit. This test is designed to detect and differentiate between multiple strains of Influenza A and B using Co-Diagnostics' proprietary Co-Primers technology. The new test marks another achievement in CoSara's efforts to expand its diagnostic offerings in India as they prepare for further growth with the upcoming Co-Dx PCR platform. However, the Co-Dx PCR Pro instrument remains under FDA review and is not yet commercially available.
Read more →CODXCo-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Webcast
Co-Diagnostics, Inc. has announced that it will release its fourth quarter and full year 2023 financial results on March 14, 2024. Following the release, the company will host a conference call and webcast at 4:30 p.m. ET to discuss these results with analysts and investors. CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson will participate in this call. The event will be accessible via webcast on the company’s website, with a recording available afterwards for those unable to attend live.
Read more →CODXCo-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for February 2024
Co-Diagnostics, Inc. announced its participation in various industry conferences in February 2024, aimed at showcasing its PCR technology designed to enhance diagnostic accessibility. Key events include a workshop in India on tuberculosis diagnostics and the Medlab Middle East meeting in Dubai, which caters to the global laboratory community. The company is also exploring regulatory approvals in Saudi Arabia to expand its market presence. Despite positive engagement, the Co-Dx PCR platform remains under FDA review, which carries associated risks.
Read more →CODXThe Co-Dx™ PCR platform
Co-Diagnostics is nearing the launch of its Co-Dx PCR platform, designed to provide affordable and accessible PCR testing. The platform enables rapid diagnosis of infectious diseases with results delivered to users' smartphones in about 30 minutes. With a focus on democratizing diagnostics globally, the platform is currently under FDA review.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at CES 2024 January 9-12
Co-Diagnostics, Inc. announced it will host a booth at CES 2024 from January 9-12 in Las Vegas, showcasing its Co-Dx PCR at-home and point-of-care platform. The company recently submitted tests for Emergency Use Authorization to the FDA, including the Co-Dx PCR Pro and COVID-19 test. Attendees can also learn about future products targeting tuberculosis, HPV, and respiratory viruses. The platform and associated tests are currently under regulatory review and not available for sale.
Read more →CODX▲ +23.5%on this news
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro
Co-Diagnostics, Inc. has submitted its Co-Dx PCR COVID-19 test and instrument for Emergency Use Authorization from the FDA. This platform aims to enhance the accessibility of PCR diagnostics for point-of-care and at-home use. The submission includes innovative technology that provides rapid results via a mobile app. However, the company faces uncertainties regarding FDA approval and the development of additional tests.
Read more →CODX▲ +7.3%on this news· ran to +18% by day 3
Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023
Co-Diagnostics, Inc. will present at the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023. CEO Dwight Egan is scheduled to discuss the company's progress on its upcoming Co-Dx at-home and point-of-care PCR platform. The event also includes opportunities for institutional investors to engage in one-on-one meetings with company representatives. The new PCR platform is currently under review by regulatory bodies and is not yet available for sale.
Read more →CODXCo-Diagnostics, Inc. Reports Third Quarter 2023 Financial Results Receives grant award from the Bill & Melinda Gates Foundation in the amount of $9.0M for the development of tuberculosis test on Co-Dx PCR platform.
Co-Diagnostics, Inc. reported its financial results for the third quarter of 2023, showing a decline in revenue due to reduced demand for COVID-19 testing. The company announced that it received a $9 million grant from the Bill & Melinda Gates Foundation to develop a tuberculosis test on its Co-Dx PCR platform. Despite a financial loss, Co-Diagnostics expressed optimism for future growth, highlighting the potential of their new platform and the upcoming submission for FDA emergency use authorization. The company is also diversifying its test indications beyond COVID-19.
Read more →CODXCo-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in Development
Co-Diagnostics, Inc. has received an $8.976 million grant from the Bill & Melinda Gates Foundation to support the development of a tuberculosis test for its Co-Dx PCR platform. This funding will assist in regulatory and clinical validation, increase manufacturing capacity, and enhance platform software. The initiative aligns with the WHO's push for affordable, high-quality TB diagnostics and aims to address the significant number of undiagnosed TB cases. Co-Dx's efforts are part of a broader commitment to combat the global TB epidemic.
Read more →CODXCo-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for November 2023
Co-Diagnostics, Inc. has announced its participation in several industry conferences and events for November 2023, aiming to promote its Co-Dx PCR platform technology. Key events include the Utah Life Sciences Summit, the Association for Molecular Pathology meeting, and the MEDICA trade fair in Düsseldorf. At these events, the company plans to showcase developments in point-of-care diagnostics. The initiatives reflect Co-Diagnostics' commitment to enhancing the accessibility of PCR diagnostics in a post-pandemic landscape.
Read more →CODXCo-Diagnostics, Inc. Announces Third Quarter 2023 Earnings Release Date and Webcast
Co-Diagnostics, Inc. announced that it will report its third quarter 2023 earnings on November 9, 2023, after market close. A conference call and webcast will be held at 4:30 p.m. ET the same day to discuss the financial results with analysts and institutional investors. Key management including the CEO and CFO will participate in the call, demonstrating the company's commitment to investor relations and transparency. The events will be accessible through the company's website, with options for both live participation and recorded access.
Read more →CODX▲ +5.8%on this newsshared move
Co-Diagnostics, Inc. to Host Booth at CASMET Symposium October 23-25
Co-Diagnostics, Inc. will host a booth at the Caribbean Association of Medical Technologies (CASMET) Scientific Symposium from October 23-25, 2023, in Barbados. The company aims to enhance accessibility to high-quality diagnostics in the Caribbean region. They are featuring their Co-Dx PCR Home platform, which is undergoing clinical evaluations for FDA submission. However, the platform is not yet available for sale, and the company's forward-looking statements involve various uncertainties.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at Medlab Africa 2023 in Johannesburg, South Africa
Co-Diagnostics, Inc. will host a booth at Africa Health/Medlab Africa in Johannesburg from October 17-19, 2023. This conference is notable as the largest gathering of healthcare industry professionals in the sub-Saharan region. The company aims to leverage insights from the event to launch its upcoming Co-Dx PCR Home™ platform, which includes tests for COVID-19 and tuberculosis. Support from the Bill & Melinda Gates Foundation for the TB test development further highlights the significance of this initiative.
Read more →CODXCo-Diagnostics, Inc. to Participate in the 2023 UHCA/UCAL Fall Convention & Expo on Sept 27-28
Co-Diagnostics, Inc. will participate in the 2023 UHCA/UCAL Fall Convention & Expo as a platinum sponsor. The event will take place on September 27-28, 2023, in Sandy, Utah, focusing on skilled nursing, assisted living, and intermediate care facilities. CEO Dwight Egan is set to present the Co-Dx PCR Home platform, which is currently under FDA review and not yet available for sale. Attendees can learn more about Co-Diagnostics' diagnostic products at their booth.
Read more →CODXCo-Diagnostics, Inc. to Participate in 6th ACTC Conference in Skiathos, Greece
Co-Diagnostics, Inc. will be hosting a booth and presenting at the 6th Advances in Circulating Tumor Cells conference in Skiathos, Greece. The conference will cover the latest advancements in liquid biopsy techniques, with a focus on circulating tumor cells and circulating DNA. Co-Diagnostics will share research on their Co-Primers technology and discuss their upcoming Co-Dx PCR Home platform, which aims to enhance infectious disease diagnosis. However, the PCR Home platform is still under FDA review and is not yet commercially available.
Read more →CODXCo-Diagnostics, Inc. to Participate in Gilmartin Group Annual Emerging Growth Showcase on Sept 21
Co-Diagnostics, Inc. will participate in the Gilmartin Group Annual Emerging Growth Showcase on September 21, 2023. CEO Dwight Egan is set to discuss the progress of the forthcoming Co-Dx PCR Home platform during a fireside chat. The platform is currently under FDA review and is not available for consumer purchase at this time. This event highlights the company's advancements in molecular diagnostics technology.
Read more →CODXCo-Diagnostics, Inc. to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023
Co-Diagnostics, Inc. announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023. CEO Dwight Egan will present on the Co-Dx PCR Home platform, currently under FDA review and not available for sale. The presentation can be accessed online for registered institutional investors and industry professionals. Additionally, the company will engage in one-on-one meetings with H.C. Wainwright representatives.
Read more →CODXTuberculosis in India
India faces a significant tuberculosis burden, accounting for about 25% of global cases. In 2021, there were approximately 2.59 million incidences and over 500,000 deaths due to TB. Despite advancements in diagnostics, the COVID-19 pandemic has hindered progress, redirecting funding and increasing undiagnosed cases. Co-Diagnostics aims to enhance TB diagnostics through its upcoming PCR platform.
Read more →CODXCo-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer
Co-Diagnostics, Inc. has appointed Ivory Chang as the Chief Regulatory Affairs Officer. With extensive experience in regulatory affairs from major companies like Roche and Thermo Fisher Scientific, Chang aims to leverage her skills to navigate regulatory submissions for the company's expanding pipeline. CEO Dwight Egan expressed optimism about her contributions to advancing Co-Dx's vision for accessibility in molecular diagnostics. The Co-Dx PCR Home platform, which is currently under FDA review, is part of this future portfolio.
Read more →CODXThe Co-Dx™ PCR Pro™
The Co-Dx PCR Pro™ provides rapid, point-of-care PCR testing for infectious diseases, including COVID-19. This innovative platform allows users to obtain results quickly without the need for laboratory processing. It aims to enhance healthcare delivery, particularly in assisted living and skilled nursing facilities, by ensuring timely diagnosis and treatment. Regulatory approval is required before the product can be marketed.
Read more →CODXInvisible efforts, life-saving results
The article discusses the resurgence of malaria cases in the U.S. and emphasizes the critical role of mosquito abatement districts (MADs) in controlling vector-borne diseases. Co-Diagnostics offers PCR testing solutions that enable MADs to conduct efficient onsite testing, thereby improving public health responses to mosquito-borne illnesses. The need for such technologies is underscored by climate change's impact on mosquito activity.
Read more →CODXCo-Diagnostics, Inc. to Present at 15th Next Generation Dx Summit in Washington, D.C.
Co-Diagnostics, Inc. announced its participation in the 15th Annual Next Generation Dx Summit, taking place in Washington, D.C. from August 21-23, 2023. The company will sponsor, present, and host a booth at the event, focusing on advancements in molecular diagnostics. CEO Dwight Egan is set to discuss the Co-Dx PCR Home™ platform during a luncheon presentation, which is currently under FDA review. The summit will cover key topics such as point-of-care testing and companion diagnostics.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at Medlab Asia Conference in Bangkok, Thailand
Co-Diagnostics, Inc. announced its participation in the Asia Health/Medlab Asia 2023 conference in Bangkok from August 16-18. The company will host a booth to showcase its advanced Co-Primer™ PCR technology and upcoming Co-Dx PCR Home testing platform, which is currently under FDA review. The event is expected to attract over 7,500 attendees from the healthcare and laboratory sectors, providing a valuable networking opportunity for the company.
Read more →CODXWhy should your laboratory be using Co-Primers™ products
The article emphasizes the importance of specificity in PCR testing for clinical laboratories and research institutions. It introduces Co-Primers technology by Co-Dx, which enhances specificity and reduces false results in PCR reactions. This patented technology is crucial for accurate infectious disease diagnostics and supports effective treatment strategies and public health initiatives.
Read more →CODX▼ -6.9%on this newsshared move
Co-Diagnostics, Inc. Reports Second Quarter 2023 Financial Results Co-Dx receives grant awards from the Bill & Melinda Gates Foundation; NIH RADx Tech to develop tests on our new Co-Dx PCR Home platform
Co-Diagnostics, Inc. reported its second quarter financial results for 2023, revealing a drastic drop in revenue primarily due to reduced demand for COVID-19 tests. The company recorded significant operating and net losses, with a combined loss of nearly $12 million. However, the company announced positive developments, including substantial grants from the NIH and the Bill & Melinda Gates Foundation aimed at advancing its Co-Dx PCR Home platform and other diagnostic tests. Co-Diagnostics is also on track for an FDA submission related to this platform by year-end while expanding its manufacturing capabilities.
Read more →CODX▲ +18.2%on this news
Bill & Melinda Gates Foundation awards 70+ grants
In July 2023, the Bill & Melinda Gates Foundation awarded over 70 grants, emphasizing support for omics and diagnostics projects. The article highlights specific details about the awardees, funding amounts, project durations, and titles. This initiative aims to foster advancements in health and technology.
Read more →CODX▼ -6.9%on this newsshared move
Co-Diagnostics, Inc. Announces Second Quarter 2023 Earnings Release Date and Webcast
Co-Diagnostics, Inc. has announced the date for its second quarter 2023 earnings release, set for August 10, 2023, post-market. A conference call and webcast will follow at 4:30 p.m. ET for discussions with analysts and institutional investors. The company, known for its patented molecular diagnostic technologies, continues to engage with stakeholders while its Co-Dx PCR Home platform awaits FDA review.
Read more →CODX▲ +9.9%on this news· ran to +23% by day 1
Co-Diagnostics, Inc. to Host Booth and Discuss Recent Grant Awards at AACC 2023 in Anaheim, CA
Co-Diagnostics, Inc. is set to showcase its advancements at the AACC 2023 in Anaheim, CA, including a booth and a presentation on recent grant activities. The company aims to discuss its pipeline of diagnostic tests, particularly for respiratory infections and HPV, alongside the Co-Dx PCR Home platform, which is currently under FDA review. CEO Dwight Egan will address new grant awards during the presentation scheduled for July 25. The event highlights Co-Dx's commitment to advancing molecular diagnostics amidst ongoing clinical evaluations.
Read more →CODXCo-Dx™ awarded $2.3M from Bill & Melinda Gates Foundation
Co-Dx has been awarded $2.3 million in grants from the Bill & Melinda Gates Foundation. The funding includes $1.3 million for tuberculosis tests and $987,000 for HPV tests. These grants will help complete the tests for the Co-Dx PCR Home™ platform, targeting priority global markets.
Read more →CODXCo-Diagnostics, Inc. Announces Recent Grant Awards
Co-Diagnostics, Inc. has announced the awarding of grants from the Bill & Melinda Gates Foundation aimed at supporting the completion of tuberculosis (TB) and HPV tests for its Co-Dx PCR Home™ platform. The grants, totaling $2.32 million, will advance diagnostic technologies intended for markets with high needs. The CEO emphasized the importance of the platform in addressing infectious diseases, particularly TB and HPV, which have significant health impacts globally. However, the platform is still undergoing regulatory review and is not yet available for public use.
Read more →CODX▲ +10.5%on this newsshared move
Co-Dx™ awarded $1.2M from RADx program
Co-Dx™ has been awarded $1.2 million by the NIH's RADx Tech program to advance its upper respiratory panel. This multiplex test will detect influenza A/B, COVID-19, and respiratory syncytial virus using the Co-Dx PCR Home™ Testing Platform. The funding will aid in completing the assay's development and preparing for clinical trials.
Read more →CODX▲ +10.5%on this newsshared move
Co-Diagnostics, Inc. Awarded Funding for Co-Dx PCR Home Platform from NIH RADx® Tech Program
Co-Diagnostics, Inc. has received a $1.2 million grant from the NIH's RADx Tech program to complete its upper respiratory panel multiplex test for the Co-Dx PCR Home platform. This funding will support the development of tests for flu A/B, COVID-19, and RSV, which are set to begin clinical trials. The company emphasizes its commitment to improving diagnostic accessibility and affordability as it navigates the post-pandemic landscape. The Co-Dx PCR Home is currently undergoing evaluations in preparation for FDA submission.
Read more →CODX▼ -5.7%on this news
Co-Diagnostics, Inc. Reports First Quarter 2023 Financial Results Clinical trials for Co-Dx PCR Home platform remain on track; Solid cash position and grant funding support long-term strategy
Co-Diagnostics, Inc. reported its financial results for Q1 2023, showing a significant decline in revenue primarily due to decreased demand for COVID-19 tests. The company had a net loss of $5.8 million, contrasting sharply with the previous year's net income. Despite these challenges, progress continues on the Co-Dx PCR Home platform, with plans for clinical evaluations and FDA submission by year-end. The company also highlighted its strong cash position and grant support for future initiatives.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at Senior Living Executive Conference in New Orleans, LA
Co-Diagnostics, Inc. is participating in the Argentum's 2023 Senior Living Executive Conference in New Orleans, showcasing its innovative Co-Dx PCR Home™ testing platform. The conference, running from May 8-10, is aimed at professionals in senior living, featuring over 750 exhibiting companies. Attendees can learn about Co-Diagnostics' pipeline for respiratory disease diagnostics, which includes tests for COVID-19, influenza, RSV, and tuberculosis. The Co-Dx PCR Home platform is currently under FDA review and is not yet available for sale.
Read more →CODXCo-Diagnostics, Inc. Announces First Quarter 2023 Earnings Release Date and Webcast
Co-Diagnostics, Inc. will release its first quarter 2023 financial results on May 11, 2023. A conference call and webcast will occur at 4:30 p.m. ET to discuss these results with analysts and institutional investors. Management will include the CEO, CFO, and Head of Investor Relations. The results will provide valuable insights into the company's financial health and strategic developments.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at 67th Annual CARPHA Conference April 27-29
Co-Diagnostics, Inc. will host a booth at the Caribbean Public Health Agency's 67th Annual Health Research Conference from April 27-29, 2023, in the Bahamas. This event, the largest health research conference in the English-speaking Caribbean, aims to enhance communication among health scientists and policymakers. Co-Diagnostics will showcase its infectious disease products and upcoming Co-Dx PCR Home testing platform, although the platform is still subject to FDA review and not yet available for sale. This marks the company's ongoing commitment to participating in key health events since 2016.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at ECCMID 2023 April 15-18 in Copenhagen, Denmark
Co-Diagnostics, Inc. will host a booth at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen, Denmark. This prominent event is anticipated to draw over 14,000 attendees, providing a platform for industry experts to share their latest research and guidelines. Co-Dx aims to leverage this opportunity to interact with potential customers regarding their real-time PCR products and upcoming Co-Dx PCR Home platform, which is currently under FDA review and not yet available for sale.
Read more →CODXCo-Diagnostics, Inc. to CEO to Deliver Keynote Address at 2023 MarketsandMarkets Conference in London, England
Co-Diagnostics, Inc. announced that its CEO, Dwight Egan, will deliver the keynote address at the 4th Annual MarketsandMarkets Conference in London on March 23, 2023. Egan will present on the company's forthcoming Co-Dx PCR Home testing platform, which is currently undergoing clinical evaluations and awaiting FDA review. The event aims to gather professionals from various sectors to discuss future directions in diagnostic research. Co-Diagnostics will also have a booth at the conference to showcase its products.
Read more →CODX▼ -16.2%on this news· ran to -45% by day 3shared move
Co-Diagnostics, Inc. to Host Booth at 10th Gene Quantification Event in Munich, Germany, March 20-22
Co-Diagnostics, Inc. will host a booth at the 10th Gene Quantification Event in Munich from March 20-24. The company's Scientific Advisory Board Chair, Dr. Carl Wittwer, will present on the topic of at-home PCR testing for SARS-CoV-2. The presentation will highlight the feasibility of at-home testing using the new Co-Dx PCR Home platform, which is currently under FDA review. The event will feature various topics related to molecular diagnostics and offer an opportunity for attendees to learn more about Co-Diagnostics' products.
Read more →CODXCo-Diagnostics, Inc. Reports Full Year 2022 Financial Results Full-year Results Impacted by Lower Demand for COVID-19 Testing Announced Initiation of Clinical Evaluations for Co-Dx PCR Home Platform
Co-Diagnostics, Inc. recently reported its financial results for the full year 2022, highlighting a steep decline in revenue primarily due to decreased demand for COVID-19 tests. The company experienced an operating loss of $27 million, a significant drop from the previous year's profits. Despite these challenges, Co-Diagnostics announced the initiation of clinical evaluations for their Co-Dx PCR Home platform, which they believe will establish new standards in at-home testing. The company retains a healthy cash position and is focusing on future innovations.
Read more →CODXCO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST
Co-Diagnostics, Inc. has announced that it will release its fourth quarter and full year 2022 financial results on March 16, 2023, after market close. Following the release, the company will conduct a conference call and webcast at 4:30 p.m. EDT to discuss these results. The call will feature key management personnel, including the CEO and CFO, and will be accessible to analysts and institutional investors.
Read more →CODXCo-Diagnostics, Inc. to Present and Host Booth at TRI-CON in San Diego, CA, March 6-8
Co-Diagnostics, Inc. will present and host a booth at the 30th Molecular and Precision Med TRI-CON from March 6-8, 2023, in San Diego, CA. As a Premier Sponsor, Co-Dx will deliver a Lunch Presentation focusing on its new Co-Dx PCR Home platform, which is undergoing clinical evaluations. The company is ramping up its marketing efforts in anticipation of regulatory approvals for commercialization. The event provides significant networking opportunities for the diagnostics and precision medicine community.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at 89th Annual AMCA Conference in Reno, NV on Feb 28-March 3
Co-Diagnostics, Inc. will host a booth at the 89th annual American Mosquito Control Association (AMCA) conference from February 28 to March 3 in Reno, Nevada. This conference is a significant event for education and networking among mosquito control professionals and offers Co-Diagnostics an opportunity to present its vector control PCR products. The company has noted growth in laboratory installations and reagent purchases over the past year, indicating a positive trajectory in its business activities.
Read more →CODXCo-Diagnostics, Inc. Initiates Clinical Evaluations for its At-Home and Point-of-Care Co-Dx PCR Home™ Platform
Co-Diagnostics, Inc. has commenced clinical evaluations for its Co-Dx PCR Home™ platform, which aims to offer at-home and point-of-care COVID-19 testing. The platform represents extensive research and development efforts, integrating proprietary technologies to enhance testing capabilities. The CEO has expressed optimism about the potential global impact of this innovation, particularly in regions lacking high-quality diagnostic access. However, timelines for completion of the evaluations remain unspecified due to patient enrollment challenges.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at Medlab Middle East 2023 in Dubai on February 6-9
Co-Diagnostics, Inc. will host a booth at the Medlab Middle East 2023 trade show from February 6-9 in Dubai. The conference is expected to attract over 20,000 attendees and 700 exhibitors globally. Co-Diagnostics anticipates that this venue will facilitate the introduction of its products to a diverse array of international customers, particularly in the Middle East market.
Read more →CODXCo-Diagnostics, Inc. Commemorates Third Anniversary of the Completion of its First COVID-19 Test Design
Co-Diagnostics, Inc. has commemorated the third anniversary of its first COVID-19 test design, which has remained effective despite numerous variants. The company has successfully sold over 33 million tests globally and is preparing to participate in the Life Sciences Day on the Hill event. CEO Dwight Egan expressed pride in the company's achievements during the pandemic and highlighted the development of their upcoming at-home PCR testing platform. The new platform is currently in pre-clinical evaluations ahead of FDA review.
Read more →CODXCo-Diagnostics, Inc. to Host Booth at CES 2023 January 5-8
Co-Diagnostics, Inc. will be hosting a booth at CES 2023 from January 5-8 in Las Vegas. The company is set to exhibit its Co-Dx PCR at-home and point-of-care platform, which is undergoing final preparations for clinical evaluations. This platform is aimed for submission to the FDA for regulatory authorization. Interested attendees can visit Booth #8063 to learn more about Co-Diagnostics and its products.
Read more →CODXCo-Diagnostics, Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022
SALT LAKE CITY, Nov. 30, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be present
Read more →CODXCo-Diagnostics, Inc. to Host Booth at MEDICA 2022 Trade Fair in Düsseldorf, Germany
SALT LAKE CITY, Nov. 14, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth thi
Read more →CODXCo-Diagnostics, Inc. Reports Third Quarter 2022 Financial Results Nearing commencement of clinical evaluations for the Co-Dx PCR Home platform COVID-19 test volumes continue to impact third quarter results
Inc. Reports Third Quarter 2022 Financial Results commencement of clinical evaluations for the Co-Dx PCR Home platform test volumes continue to impact third quarter results LAKE CITY, November 10, 2022- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with
Read more →CODXCo-Diagnostics, Inc. to Host Booth at AMP This Week in Phoenix, AZ
SALT LAKE CITY, Nov. 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company is hosting a booth
Read more →CODXCo-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer
SALT LAKE CITY, Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Por
Read more →CODXCO-DIAGNOSTICS, INC. ANNOUNCES THIRD QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST
SALT LAKE CITY, Oct. 27, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2022 results on Thursday, Novem
Read more →CODXCo-Diagnostics, Inc. to Host Booth at Medlab Africa on Oct 26-28 in South Africa
SALT LAKE CITY, Oct. 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a
Read more →CODXCo-Diagnostics, Inc. to Host Booths at Conferences in Washington, D.C. and Bangkok, Thailand
SALT LAKE CITY, Oct. 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting bo
Read more →CODX▲ +5.8%on this news
Co-Diagnostics, Inc. to Sponsor, Present, and Host Booth at 66th Annual CARPHA Conference on Sept 15-17 in Jamaica
SALT LAKE CITY, Sept. 14, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be sponsorin
Read more →CODXCo-Diagnostics, Inc. to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
SALT LAKE CITY, Sept. 12, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presen
Read more →CODXCo-Diagnostics, Inc. to Host Booth at Medical Fair Asia 2022 in Singapore on Aug 31-Sep 2
SALT LAKE CITY, Aug. 31, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or Co-Dx), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the u
Read more →CODXCo-Diagnostics, Inc. to Present at 14th Next Generation Dx Summit in Washington, D.C.
SALT LAKE CITY, Aug. 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hos
Read more →CODXCo-Diagnostics, Inc. Reports Second Quarter 2022 Financial Results Second quarter results impacted by volume declines; Further progress on the development of the Co-Dx PCR Home platform
Inc. Reports Second Quarter 2022 Financial Results quarter results impacted by volume declines; progress on the development of the Co-Dx PCR Home platform LAKE CITY, August 11, 2022- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented p
Read more →CODXCO-DIAGNOSTICS, INC. ANNOUNCES SECOND QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST
SALT LAKE CITY, Aug. 2, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2022 results on Thursday, Augus
Read more →CODXCo-Diagnostics, Inc. to Participate in Yale University SalivaDirect™ Conference Held July 28-29 in Chicago
SALT LAKE CITY, July 27, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be attending and speaking
Read more →CODXCo-Diagnostics, Inc. to Announce Expansion of OEM Agreement with Bio Molecular Systems at AACC
SALT LAKE CITY, July 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global
Read more →CODXCo-Diagnostics, Inc. to Host Booth at AACC Held July 24-28 in Chicago
The Company will also be providing an update to its distributors and other customers on July 26 at 11 am CT. SALT LAKE CITY, July 20, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented pla
Read more →CODXCo-Diagnostics, Inc. Announces Shipment of Monkeypox Virus Test
SALT LAKE CITY, July 11, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has shipped testing reagent
Read more →CODXCo-Diagnostics, Inc. to Present at 29th International Biodetection Technologies Virtual Conference
SALT LAKE CITY, June 28, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting this week
Read more →CODXCo-Diagnostics, Inc. to Present at Sidoti Summer Small Cap Virtual Conference
SALT LAKE CITY, June 15, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, C
Read more →CODXCo-Diagnostics, Inc. to Host Booth at MEDEXPO Africa 2022 in Nairobi, Kenya on June 9-11
SALT LAKE CITY, June 9, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the
Read more →CODX▲ +7.3%on this news· ran to +19% by day 1
Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus
SALT LAKE CITY, May 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the principal
Read more →CODXCo-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 Global Investment Conference on May 23-26
SALT LAKE CITY, May 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenti
Read more →CODX▲ +5.3%on this news· ran to +34% by day 3
Co-Diagnostics Reports Solid First Quarter 2022 Financial Results Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34
Reports Solid First Quarter 2022 Financial Results results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 LAKE CITY, May 12, 2022- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for t
Read more →CODXCo-Diagnostics, Inc. to Host Booth at Medical Fair Brasil 2022 in São Paulo on May 3-6
SALT LAKE CITY, May 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the
Read more →CODXCO-DIAGNOSTICS, INC. ANNOUNCES FIRST QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST
SALT LAKE CITY, April 28, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2022 results on Thursday, May
Read more →CODXCo-Diagnostics, Inc. to Host Booth at ECCMID 2022 in Lisbon, Portugal on April 23-26
SALT LAKE CITY, April 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at t
Read more →CODXCo-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis C Viral Load Test
SALT LAKE CITY, April 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or th
Read more →CODXCo-Diagnostics Reports Full Year 2021 Financial Results Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY'22
Reports Full Year 2021 Financial Results Record Full Year Revenue of $97.9 Million; in Sales Momentum Provides Foundation to Achieve Solid FY'22 LAKE CITY, March 24, 2022-Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for
Read more →CODXCo-Diagnostics, Inc. to Present at MarketsandMarkets Conference on March 23-24 in London, England
SALT LAKE CITY, March 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will present at the 3rd Annual Marketsan
Read more →CODX▲ +6.7%on this newsshared move
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
SALT LAKE CITY, March 17, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is pleased to announce today that it has made several strategic
Read more →CODX▲ +13.1%on this news· ran to +30% by day 3shared move
Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program Salt Lake City, Utah
Inc. Announces Authorization of $30 Million Share Repurchase Program Lake City, Utah - March 15, 2022 - Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, annou
Read more →CODXCO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 EARNINGS RELEASE DATE AND WEBCAST
SALT LAKE CITY, March 14, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2021 results on
Read more →CODX▼ -5.7%on this news· ran to -16% by day 3
Co-Diagnostics, Inc. to Sponsor and Present at Molecular Med Tri-Con 2022
SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be a premium sponsor of the upcoming
Read more →CODXCo-Diagnostics, Inc. to Host Booth at Life Sciences Day on the Hill on February 16 at the Utah State Capital
SALT LAKE CITY, Feb. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming L
Read more →CODXCo-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis B Viral Load Test
SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the
Read more →CODXCo-Diagnostics, Inc. to Host Booth at Medlab Middle East 2022 in Dubai on January 24-27
SALT LAKE CITY, Jan. 21, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming M
Read more →CODXCo-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for High-Risk HPV Multiplex Test
SALT LAKE CITY, Jan. 13, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the
Read more →CODXCo-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 BioConnect Virtual Conference on January 10-13
SALT LAKE CITY, Jan. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be featured at the H.
Read more →CODXCo-Diagnostics, Inc. Announces Completion of the Acquisition of all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform
SALT LAKE CITY, Dec. 31, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the acquisition of Idaho Mo
Read more →CODXCo-Diagnostics, Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform Definitive merger agreements provide the Company with all existing and future assets, future
Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property rights of the platform, creating a full
Read more →CODXCo-Diagnostics JV CoSara Receives Clearance from Indian Regulators for ABC Multiplex Test
SALT LAKE CITY, Dec. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the
Read more →CODXCo-Diagnostics, Inc. Reports that Suite of COVID-19 Diagnostics Not Affected by Heavily Mutated Omicron Variant
SALT LAKE CITY, Nov. 29, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, reported today that none of the mutations in the heavily mutated
Read more →CODXCo-Diagnostics, Inc. to Host Booth at MEDICA 2021 Trade Fair in Düsseldorf, Germany
SALT LAKE CITY, Nov. 15, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at t
Read more →CODXCo-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38
Reports Continued Strength in Third Quarter 2021 Financial Results quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38 LAKE CITY, November 11, 2021-Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diag
Read more →CODXCo-Diagnostics, Inc. Logix Smart™ COVID-19 2-Gene Test Approved for Use in the United Kingdom
SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ SARS-CoV-2 2-Gene multiplex test has been validated ac
Read more →CODXCo-Diagnostics, Inc. Announces Third Quarter 2021 Earnings Release Date And Webcast
SALT LAKE CITY, Oct. 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2021 results on Thursday, Novem
Read more →CODXCo-Diagnostics JV CoSara Receives Clearance from Indian Regulators for Dengue/Chikungunya Multiplex Test
SALT LAKE CITY, Oct. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the
Read more →CODXCo-Diagnostics, Inc. to Introduce At Home/Point of Care Device at AACC on Sept 28
SALT LAKE CITY, Sept. 27, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be introducing its upcoming at-h
Read more →CODXCo-Diagnostics, Inc. Announces Corporate Rebranding Following Period of Transformative Growth and Expansion
SALT LAKE CITY, Sept. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that following its recent transformative growth,
Read more →CODXCo-Diagnostics, Inc. to Present at ACTC Liquid Biopsy Conference in Kalamata, Greece
SALT LAKE CITY, Sept. 21, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company representatives will be presenti
Read more →CODXCo-Diagnostics, Inc. Logix Smart™ ABC Test Authorized for Use in Mexico
SALT LAKE CITY, Sept. 21, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ Influenza A/Influenza B/COVID-19 "ABC" Test has been
Read more →CODXCo-Diagnostics, Inc. to Present at Sidoti Virtual Investor Conference
SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head
Read more →CODXCo-Diagnostics JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests
SALT LAKE CITY, Sept. 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or th
Read more →CODXCo-Diagnostics, Inc. CEO to Participate in Panel Discussion with Scott Gottlieb, M.D., at H.C. Wainwright 2021 Annual Global Investor Conference
SALT LAKE CITY, Sept. 13, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate
Read more →CODXCo-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy
SALT LAKE CITY, Sept. 8, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Italian researchers to
Read more →CODXCo-Diagnostics, Inc. To Present At 13th Next Generation Dx Summit In Washington, D.C.
SALT LAKE CITY, Aug. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting and hosting a booth
Read more →CODXCo-Diagnostics Reports Strong Second Quarter 2021 Financial Results Solid quarterly results highlighted by revenue of $27.4 million, pre-tax income of $11.9 million and diluted EPS of $0.33
Reports Strong Second Quarter 2021 Financial Results quarterly results highlighted by revenue of $27.4 million, pre-tax income of $11.9 million and diluted EPS of $0.33 LAKE CITY, August 12, 2021-Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique
Read more →CODXCo-Diagnostics, Inc. Announces Second Quarter 2021 Earnings Release Date And Webcast
SALT LAKE CITY, Aug. 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2021 results on Thursday, Augus
Read more →CODXCo-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer™ Patent
SALT LAKE CITY, July 22, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its suite of intellectual property protectio
Read more →CODXCo-Diagnostics, Inc Receives CE Marking for Direct Saliva SARS-CoV-2 Test
SALT LAKE CITY, June 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ SARS-CoV-2 DS (Direct Saliva) has obtained
Read more →CODXCo-Diagnostics, Inc. to Present at Upcoming Technology and Health Research Conferences
SALT LAKE CITY, June 15, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting virtually this week
Read more →CODXCo-Diagnostics Reports First Quarter 2021 Financial Results Strong quarterly results highlighted by revenue of $20.0 million, pre-tax income of $9.9 million and diluted EPS of $0.26
Reports First Quarter 2021 Financial Results quarterly results highlighted by revenue of $20.0 million, pre-tax income of $9.9 million and diluted EPS of $0.26 LAKE CITY, May 13, 2021-Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented
Read more →CODXCo-Diagnostics, Inc. Announces First-Quarter 2021 Earnings Release Date and Webcast
SALT LAKE CITY, May 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first-quarter 2021 results on Thursday, May 13,
Read more →CODXCo-Diagnostics, Inc. and Partner CRL to Discuss Saliva Testing and Future Applications of PCR in 360Dx Webinar
SALT LAKE CITY, April 29, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be accompanying Dr. Heather Fehling, Chief Sc
Read more →CODXCo-Diagnostics, Inc. JV CoSara Diagnostics Recognized for Work Combating COVID-19 Surge in India
SALT LAKE CITY, April 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Indian manufacturing facility, CoSara Diagnostics
Read more →CODXCo-Diagnostics, Inc. Test Performance Demonstrated by Australian Researchers in Peer-Reviewed Publication
SALT LAKE CITY, April 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Australian researchers
Read more →CODXCo-Diagnostics, Inc. CEO Discusses Company Strategy for the Future with Yahoo! Finance
SALT LAKE CITY, March 31, 2021 /PRNewswire/ -- The CEO of Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, appeared yesterday on Yahoo! Finance to comment on the Company's recently-relea
Read more →CODXCo-Diagnostics Reports Fourth-Quarter and Full-Year 2020 Financial Results Record quarterly results highlighted by revenue of $27.1 million and pre-tax income of $15.8 million SALT LAKE CITY, UTAH
Reports Fourth-Quarter and Full-Year 2020 Financial Results quarterly results highlighted by revenue of $27.1 million and pre-tax income of $15.8 million LAKE CITY, UTAH; March 25, 2021-Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patente
Read more →CODXCo-Diagnostics, Inc. Announces Fourth-Quarter and Full-Year 2020 Earnings Release Date and Webcast
SALT LAKE CITY, March 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth-quarter and full-year 2020 results on
Read more →CODXCo-Diagnostics Invited to Present at Maxim Group LLC Emerging Growth Virtual Conference
SALT LAKE CITY, March 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has been invited to present at the Ma
Read more →CODXCo-Diagnostics to Present Point-of-Care and At Home Testing Platform at Infectious Disease Diagnostics Virtual Conference
SALT LAKE CITY, March 10, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will be presenti
Read more →CODXCo-Diagnostics to Discuss Recent Company Advances at H.C. Wainwright Global Life Sciences Virtual Conference
SALT LAKE CITY, March 8, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will present at t
Read more →CODXCo-Diagnostics New Rapid PCR Point-of-Care and at Home Testing Platform to Detect Covid-19 and Other Diseases Using CoPrimer™ Technology
SALT LAKE CITY, March 2, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today the development of a new point-of-care/at home PCR diagnostic testing, scre
Read more →CODXCo-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based COVID-19 PCR Test Through Walgreens Find Care®
SALT LAKE CITY, Feb. 25, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that laboratory partner Clinical Reference Laboratory's (CRL) FDA-authorize
Read more →CODXCo-Diagnostics, Inc. Announces New Chief Financial Officer
SALT LAKE CITY, Feb. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it is pleased to welcome Brian Brown, CPA to the position of Co-Diagno
Read more →CODXCo-Diagnostics, Inc. to Present on Direct Saliva Testing Technology at Molecular Med Tri-Con
SALT LAKE CITY, Feb. 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be presenting on direct saliva testing for COVID-19 at the 28t
Read more →CODXCo-Diagnostics Completes FDA EUA Submission for Extraction-Free Saliva COVID-19 Test
SALT LAKE CITY, Jan. 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed its submission to the U.
Read more →CODXCo-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference
SALT LAKE CITY, Jan. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate i
Read more →CODXCo-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products Salt Lake City, Utah
Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products Lake City, Utah - January 6, 2021 - Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of
Read more →CODXCo-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform
SALT LAKE CITY, Dec. 22, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed principal design work for a
Read more →CODXCo-Diagnostics Announces Milestone of Over 10 Million COVID-19 Tests Sold
SALT LAKE CITY, Dec. 14, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has sold over 10 million of its Logix Sma
Read more →CODXCo-Diagnostics JV CoSara Receives Clearance from Indian FDA for COVID-19 2-Gene Multiplex Test
SALT LAKE CITY, Nov. 25, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the
Read more →CODXCo-Diagnostics, Inc. Receives CE Markings for "ABC" and SARS-CoV-2 2-Gene Multiplex Tests
SALT LAKE CITY, Nov. 17, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ ABC (Influenza A/B, SARS-CoV-2) and its Log
Read more →CODXCo-Diagnostics, Inc. Announces Q3 2020 Financial Results Including YTD Net Income per Common Share of $1.07 Company also announces receipt of CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests Salt Lake Cit
Inc. Announces Q3 2020 Financial Results Including YTD Net Income per Common Share of $1.07 also announces receipt of CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests Lake City, Utah - November 16, 2020 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnost
Read more →CODXCo-Diagnostics, Inc. CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction
SALT LAKE CITY, Nov. 11, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that a recent Company whitepaper demonstrates that the CoPrimer™
Read more →CODXCo-Diagnostics, Inc. Announces Q3 2020 Earnings Release Date and Earnings Webcast
SALT LAKE CITY, Nov. 10, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will release its third quarter 2020 earnings on November
Read more →CODXCo-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share Salt Lake City, Utah
Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share Utah - November 2, 2020 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today
Read more →CODXCo-Diagnostics, Inc. Logix Smart Kit to be Used with Newly Authorized Saline Oral Rinse Collection
SALT LAKE CITY, Oct. 2, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Access Genetics, LLC dba OralDNA® Labs, a CLIA-certified customer who u
Read more →CODXCo-Diagnostics, Inc. Provides Update on "ABC" Test for Influenza A, Influenza B, and COVID-19
SALT LAKE CITY, Sept. 24, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ ABC Test (Influenza A/Influenza B/COVID-19) is antic
Read more →CODXCo-Diagnostics, Inc. Announces Details to Access Presentation at H.C. Wainwright Global Investment Conference
SALT LAKE CITY, Sept. 11, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today announced the access details for CEO Dwight Egan's presentation on the Company's sig
Read more →CODXCo-Diagnostics, Inc. Enters into Agreement with Arches Research to Expand COVID-19 Testing Services
SALT LAKE CITY, Sept. 8, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today announced that it has entered into an agreement with Arches Research,
Read more →CODXCo-Diagnostics, Inc. Issues Operational Update
SALT LAKE CITY, Sept. 1, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, issued the following statement concerning the progress of the Company's operations. "Co-Di
Read more →CODXCo-Diagnostics, Inc. To Discuss Recent Company Growth and Upcoming Expansion Plans at H.C. Wainwright Global Investment Conference
SALT LAKE CITY, Aug. 25, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Company CEO Dwight Egan will be discussing the Company's significant g
Read more →CODXCo-Diagnostics, Inc. Receives Enhanced U.S. Patent Protection for CoPrimer Technology Used in COVID-19 Test
SALT LAKE CITY, Aug. 20, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that the United States Patent and Trademark Office has granted increased pa
Read more →CODXCo-Diagnostics, Inc. Announces Q2 2020 Results on Form 10-Q
SALT LAKE CITY, Aug. 13, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the filing of its operating results for the 3 month period ending
Read more →CODXCo-Diagnostics, Inc. Announces Q2 2020 Earnings Release Date and Earnings Webcast
SALT LAKE CITY, Aug. 11, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will release its second quarter 2020 earnings on August 1
Read more →CODXCo-Diagnostics, Inc. Logix Smart™ COVID-19 Test Authorized for Use in Australia
SALT LAKE CITY, Aug. 7, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Australia has been added to the list of countries that have authorized
Read more →CODXCo-Diagnostics, Inc. Technology to be Used in FDA-Authorized Self-Collected COVID-19 Saliva Test
SALT LAKE CITY, Aug. 3, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its partner, Clinical Reference Laboratory (CRL) has received FDA Emerg
Read more →CODXCo-Diagnostics, Inc. to Join Russell 2000® and Russell 3000® Indexes
SALT LAKE CITY, June 9, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it is expected to join the Russell 2000® Index at the conclusion of the
Read more →CODXCo-Diagnostics, Inc. to Present at COVID-19 Virtual Conference Hosted by Maxim Group on May 27, 2020
SALT LAKE CITY, May 27, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Company CEO Dwight Egan has been invited to present at The Role of Cell
Read more →CODXCo-Diagnostics, Inc. COVID-19 Test Successfully Used to Identify Coronavirus in Cancer Tissue
SALT LAKE CITY, May 26, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today the publication of a paper showing its Logix Smart™ COVID-19 Test Kit was us
Read more →CODXCo-Diagnostics, Inc. Announces Q1 2020 Results and Provides Mid-Second Quarter Update Company reports robust sales of COVID-19 tests as Co-Diagnostics generates net profit through middle of second quarter Salt Lake City,
Inc. Announces Q1 2020 Results and Provides Mid-Second Quarter Update reports robust sales of COVID-19 tests as Co-Diagnostics generates net profit through middle of second quarter Lake City, Utah - May 14, 2020 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics com
Read more →CODXCo-Diagnostics, Inc. Releases Prepared Remarks for First Quarter 2020 Conference Call
SALT LAKE CITY, May 14, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, releases the prepared remarks for the Q1 2020 conference call scheduled for May 14
Read more →CODXCo-Diagnostics, Inc. Announces Q1 2020 Earnings Release Date and Earnings Call
SALT LAKE CITY, May 12, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will release its first quarter 2020 earnings on May 14, 20
Read more →CODXCo-Diagnostics, Inc. Announces Government Approvals and Increased Orders for COVID-19 Test Kits
SALT LAKE CITY, May 4, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ Coronavirus COVID-19 Test has been approved f
Read more →CODXCo-Diagnostics, Inc. Releases COVID-19 Test Performance Data: Consistently Demonstrates 100% Sensitivity and 100% Specificity Across Independent Evaluations
SALT LAKE CITY, May 1, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today released COVID-19 test performance data demonstrating 100% sensitivity and 10
Read more →CODXCo-Diagnostics, Inc. Announces Expansion of COVID-19 Test Orders in the United States
SALT LAKE CITY, April 20, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company COVID-19 test sales in the United Sta
Read more →CODXCo-Diagnostics, Inc. COVID-19 Test Technology Validated for Use on Saliva Samples
SALT LAKE CITY, April 16, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that OralDNA® Labs, a CLIA-certified laboratory, h
Read more →CODXCo-Diagnostics, Inc. Contracts with Promega Corp for COVID-19 Test Manufacturing as Company Expands Domestic Customer Base
SALT LAKE CITY, April 14, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has contracted with Madison, Wisconsin-bas
Read more →CODXCo-Diagnostics, Inc Receives FDA Emergency Use Authorization for COVID-19 Test
SALT LAKE CITY, April 6, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ Coronavirus COVID-19 Test has obtained Emer
Read more →CODXCo-Diagnostics Announces $4.2 Million Registered Direct Offering Priced At-the-Market Salt Lake City, Utah
Announces $4.2 Million Registered Direct Offering Priced At-the-Market Lake City, Utah - February 27, 2020 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced
Read more →CODXCo-Diagnostics Announces Closing of $10.2 Million Registered Direct Offering Priced At-the-Market Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development
Announces Closing of $10.2 Million Registered Direct Offering Priced At-the-Market Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the closing of its previously announced re
Read more →CODXCo-Diagnostics Announces $10.2 Million Registered Direct Offering Priced At-the-Market Salt Lake City, Utah
Announces $10.2 Million Registered Direct Offering Priced At-the-Market Lake City, Utah - February 11, 2020 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced
Read more →CODXCo-Diagnostics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Salt Lake City, Utah
Co-Diagnostics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Salt Lake City, Utah - January 24, 2020 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic te
Read more →CODXCo-Diagnostics and CoSara to Launch IVD Products to India Market
Co-Diagnostics, in partnership with CoSara Diagnostics, is set to launch its in vitro diagnostic (IVD) products at the India Diagnostic Expo in Hyderabad from January 4-6. The tests, which received approval from the Central Drug Standard Control Organization, include diagnostics for tuberculosis, malaria, hepatitis B, hepatitis C, and HPV. This marks the formal introduction of these products to the Indian market.
Read more →CODXCo-Diagnostics, Inc. Continues to Execute on International Expansion
Co-Diagnostics, Inc. has announced its expansion into Ghana by collaborating with Dare Labs to establish the largest private molecular diagnostics laboratory in Kumasi. This partnership aims to provide affordable access to molecular diagnostics, particularly for malaria and other infectious diseases. The initiative is expected to significantly improve healthcare access for millions in the region.
Read more →CODXCo-Diagnostics, Inc. Adds to Menu of Molecular Vector Control Products
Co-Diagnostics, Inc. has launched the Vector Smart ZDC test, designed to identify Zika, dengue, and chikungunya in mosquito populations. This product addresses requests from health ministries and mosquito abatement districts across North America, Latin America, and the Caribbean. The company anticipates revenue growth from this sector, enhancing efforts to control mosquito-borne diseases.
Read more →CODXCo-Diagnostics to Present Technology Applications at 4th ACTC Liquid Biopsy Conference in Corfu, Greece
Co-Diagnostics, Inc. will showcase its CoPrimer technology for liquid biopsy applications at the 4th ACTC conference in Corfu, Greece. The presentation, titled 'Evaluation of Cooperative Primers for Rare Allele Detection,' will be delivered by CEO Dwight Egan. The company emphasizes the potential of liquid biopsy to revolutionize cancer diagnostics and improve patient outcomes.
Read more →CODXCo-Diagnostics, Inc. to Launch Vector Control Products into Midwest US at OPMA Conference
Co-Diagnostics, Inc. is set to launch its vector control testing products at the OPMA Conference in Tulsa, Oklahoma, on September 19-20. The company aims to enhance mosquito abatement efforts in the Midwest, addressing the spread of mosquito-borne diseases like West Nile virus. CEO Dwight Egan highlighted the importance of effective mosquito control programs and expressed optimism about the company's growth in the region.
Read more →CODXCo-Diagnostics, Inc. and LGC, Biosearch Technologies Expand License Agreement for CoPrimer™ Technology
Co-Diagnostics, Inc. has expanded its license agreement with LGC, Biosearch Technologies, allowing for additional research applications of its CoPrimer technology. This agreement is expected to generate increased revenue as LGC markets and distributes the products globally. Co-Diagnostics anticipates that the partnership will enhance its customer base and reduce sales costs, leveraging LGC's extensive reach.
Read more →CODXCo-Diagnostics, Inc. to Present at 21st Annual Rodman & Renshaw Global Investment Conference Sept 8-10, 2019
Co-Diagnostics, Inc. will present at the 21st Annual Rodman & Renshaw Global Investment Conference from September 8-10, 2019. CEO Dwight Egan is set to provide insights on the company's business and market progress, particularly in India. The event will facilitate one-on-one meetings for institutional investors, enhancing engagement opportunities.
Read more →CODXCo-Diagnostics, Inc. Announces New Additions to Board of Directors Salt Lake City, Utah
Inc. Announces New Additions to Board of Directors Lake City, Utah - June 27, 2019 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dr. Eugene Durenar
Read more →CODXCo-Diagnostics, Inc. Regains Compliance with NASDAQ Listing Standards Salt Lake City, Utah
Inc. Regains Compliance with NASDAQ Listing Standards Lake City, Utah - Feb 22, 2019 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has received w
Read more →CODXCo-Diagnostics, Inc. Announces Closing of $5.5 Million Registered Direct Offering Salt Lake City, Utah
Inc. Announces Closing of $5.5 Million Registered Direct Offering Lake City, Utah - February 4, 2019 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the cl
Read more →CODXCo-Diagnostics, Inc. Announces Elimination of Debt, Additional Capital Infusion SALT LAKE CITY-(BUSINESS WIRE)
Inc. Announces Elimination of Debt, Additional Capital Infusion LAKE CITY-(BUSINESS WIRE)-Jan 30, 2019-Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the sa
Read more →CODXCo-Diagnostics, Inc. and LGC, Biosearch Technologies Sign License Agreement for CoPrimer Technology Co-Diagnostics agrees to license CoPrimers for use in agricultural applications Salt Lake City, Utah
Inc. and LGC, Biosearch Technologies Sign License Agreement for CoPrimer Technology agrees to license CoPrimers for use in agricultural applications Lake City, Utah - October 30, 2018 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprie
Read more →CODXCo-Diagnostics, Inc. Announces Pricing of Initial Public Offering Salt Lake City, UT
Co-Diagnostics, Inc. Announces Pricing of Initial Public Offering Salt Lake City, UT - July 12, 2017 - Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics" or the "Company"), a molecular diagnostics company that has developed and intends to manufacture and sell reagents used fo
Read more →Competitive Position
How CODX ranks across every disease it competes inCompetitive Position is a premium feature
See how CODX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial